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Summary
Radiolabelled antiCD-20 antibodies have demonstrated single agent activity
in relapsed diffuse large B-cell lymphoma (DLBCL). The S0433 clinical trial
enrolled patients with newly diagnosed, advanced stage or bulky stage II,
histologically confirmed DLBCL. Patients received six cycles of R-CHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), two
cycles of CHOP, then iodine-131 tositumomab radioimmunotherapy con-
solidation 30–60 d after completion of chemotherapy. The primary end-
point was 2-year progression-free survival (PFS). Eighty-four eligible
patients were enrolled, and 56 patients completed the entire course of pro-
tocol treatment. Of the 84 patients evaluable for treatment response, 72
[86%, 95% confidence interval (CI): 76–92%] achieved a partial response
(n = 21) or a confirmed (n = 41) or unconfirmed (n = 10) complete
response to therapy. With a median follow-up of 39 years, the 2-year PFS
estimate is 69% and the 2-year overall survival estimate is 77%. Rituximab
levels at time of radioimmunotherapy did not correlate with toxicity or
outcome. Twenty percent of patients had double hit features (MYC+;
BCL2+) by immunohistochemistry, and had inferior outcome. These cur-
rent results suggest that the incorporation of novel agents earlier in therapy
may ultimately have greater impact in DLBCL, as early progressions, deaths
and declining performance status during CHOP chemotherapy limited the
number of patients who ultimately could benefit from radioimmunothera-
py consolidation.
Keywords: lymphoma, chemotherapeutic approaches, diffuse large B cell
lymphoma, radioimmunotherapy, pharmacotherapeutics.
Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon type of non-Hodgkin lymphoma (NHL) in the United
States, and is curable with standard R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine, prednisone) che-
motherapy. Despite the improvements in outcome of DLBCL
with the routine incorporation of rituximab, high-risk sub-
groups defined by the International Prognostic Index (IPI)
continue to have inferior outcome (Ziepert et al, 2010). For
younger patients, consolidation with autologous stem cell
transplantation (ASCT) in first remission prolongs progres-
sion-free survival (PFS), and possibly improved overall sur-
vival (OS) for the highest risk patients (Stiff et al, 2013).
However, as the incidence of DLBCL increases with age, new
therapies with minimal additive toxicity are clearly needed,
particularly for patients unfit for ASCT.
Radioimmunotherapy with conjugated anti-CD20 antibod-
ies has demonstrated single-agent activity in DLBCL. In
patients with relapsed DLBCL, a phase 2 trial of ibritumo-
mab tiuxetan demonstrated a response rate of over 50%
(Morschhauser et al, 2007). We have previously demon-
strated the safety of sequential chemotherapy with CHOP
followed by consolidative radioimmunotherapy with the
iodine-131 (131I) tositumomab regimen in patients with fol-
licular lymphoma, demonstrating high response rates, and
conversion from partial response to complete response after
consolidative radioimmunotherapy (Press et al, 2006).
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We therefore designed the S0433 clinical trial, which
incorporated consolidative radioimmunotherapy with the
131I tositumomab regimen after standard R-CHOP chemo-
therapy for patients with newly diagnosed DLBCL. The
objective of trial S0433 was to estimate the 2-year PFS, in
hope of increasing the durable remission rate in patients
with aggressive lymphomas, without serious additive
toxicity.
Methods
Study registration
This Phase II multicentre trial was initiated in November
2005. The protocol was approved by the Institutional Review
Board at each site, and written consent was obtained from all
patients prior to enrollment. The study was registered with
ClinicalTrials.gov prior to enrolling patients (ClinicalTri-
als.gov Identifier: NCT00107380).
Eligibility
The original trial design limited patient inclusion to those
>60 years of age; after 17 (20% of total) patients were
enrolled, an amendment expanded the study inclusion crite-
ria to include patients >18 years of age after a competing
study for younger patients completed accrual. Eligible
patients had a previously untreated diagnosis (World Health
Organization classification) of CD20-positive advanced stage
(Stage III, IV, or bulky [>10 cm] Stage II) DLBCL with
bidimensionally measurable disease; all pathology was con-
firmed by central review. Eligible patients had adequate per-
formance status (Zubrod 0–2) and adequate renal, hepatic,
haematologic, and cardiac function. Baseline laboratory
parameters included circulating lymphoid cells <20 9 109/l.
Patients were excluded if they had a previous diagnosis of
malignancy (with the exception of basal cell or squamous
cell of the skin, in situ cervical cancer, adequately treated
Stage I or II cancer for which patient was in complete
remission, or any other cancer from which patient had been
disease-free for at least 5 years); or clinical evidence of cen-
tral nervous system (CNS) involvement by lymphoma.
Pregnant or nursing female patients, patients known to be
human immunodeficiency virus (HIV) positive or with a
history of solid organ transplantation, and patients requiring
continuous supplemental oxygen therapy, were also
excluded.
Baseline studies
Baseline evaluation included a history and physical
examination, radiographic imaging (computerized
tomography of the chest, abdomen, and pelvis), routine
laboratory studies, bone marrow evaluation and an
electrocardiogram.
Protocol treatment
Patients were treated with standard R-CHOP chemotherapy
as follows: every 21 d for the first 6 cycles (Coiffier et al,
2002); rituximab was omitted from cycles 7 and 8 to limit
antigen binding competition as observed in murine studies
(Gopal et al, 2008). 131I tositumomab (Bexxar; supplied by
GlaxoSmithKline, Research Triangle Park, NC) was adminis-
tered 30–60 d after cycle 8 of CHOP, as described (Press
et al, 2003). Intrathecal methotrexate was allowed at physi-
cian discretion for CNS prophylaxis. Patients were removed
early from the protocol treatment for progressive disease,
unacceptable toxicity, failure to meet criteria for tositumo-
mab administration following completion of CHOP chemo-
therapy, or patient preference.
Criteria for response and toxicity
Restaging for response determination was performed within
4 weeks of the last cycle of CHOP (approximately Day 169),
and then again at 12 weeks post-131I tositumomab treatment
using the same imaging techniques used for baseline mea-
surements. Clinical responses were coded according to
International Workshop NHL criteria (Cheson et al, 1999).
National Cancer Institute Common toxicity criteria version 3.0
was used to grade toxicities (http://ctep.cancer.gov/protocol-
Development/electronic_applications/docs/ctcaev3.pdf[ctep.can-
cer.gov]). Patients were followed prospectively and evaluated
at 1 year, then every 6 months for 2 years, then annually for
a maximum of 5 years.
PFS was calculated from the first dose of study drug to
the first documentation of disease progression or death due
to any cause, whichever occurred first. Patients who were
alive and progression-free at the time of final data analysis
were censored at last assessment.
Correlative laboratory studies
Rituximab levels and toxicity. We utilized ELISA-0145-004, a
sandwich enzyme-linked immunosorbent assay (ELISA) for
the determination of Rituximab in human serum after cycle
8 of CHOP. The association between rituximab levels and
toxicity were evaluated by comparing the proportion of
patients with grade 3, 4 or 5 toxicities for patients with
rituximab levels above versus below the median rituximab
concentration using chi-square analysis.
Immunohistochemistry. We evaluated MYC and BCL2 pro-
tein expression and germinal center B-cell-like (GCB) versus
non-GCB status using immunohistochemistry techniques on
patient samples obtained at baseline. Studies of MYC expres-
sion were performed and scored (40% cut-off; based on min-
imum 100 cell count) as described (Johnson et al, 2012).
Cell of origin was determined using the Hans algorithm
based on stains for CD10 [Biocare (Concord, CA, USA),
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clone 56C6], BCL6 [Cell Marque (Rocklin, CA, USA), clone
GI191/A8], and MUM1 [Dako (Glostrup, Denmark), clone
MUM1p] (Hans et al, 2004).
Statistical analysis
For the primary objective, a modified intent-to-treat analysis
was performed, excluding patients determined to be ineligible.
Patients who did not receive any treatment were excluded
from evaluation of adverse events. The primary endpoint of
this study was the 2-year PFS rate. The planned statistical
design anticipated that 80 patients accrued over 15 months
with 18 months of additional follow-up would be sufficient
to estimate the 2-year PFS to within  012. The design also
specified an adjustment for important prognostic groups. We
assumed that 2-year PFS was approximately 60% for patients
older than 60 years and for younger patients (≤60 years old)
with high IPI scores (2 or higher), and approximately 85%
for patients ≤60 years with low IPI scores (0 or 1) (Pfreund-
schuh et al, 2006). If 10% of patients were in the younger
patient group (≤60 years old) with low IPI, the weighted
2-year PFS for R-CHOP would be 63%, compared to an alter-
native 20% greater (83%). Under these assumptions, an esti-
mated 2-year PFS of 73% or greater [based on the 95% upper
bound on the confidence interval (CI) using a one-arm sur-
vival design] would be sufficient to warrant further investiga-
tion (Lawless, 1982). The target value was adjusted based on
the observed frequency of prognostic groups. Eighty patients
would also be sufficient to estimate the probability of any
particular toxicity to within  011. Survival was estimated
according to the method of Kaplan and Meier (Kaplan &
Meier, 1958). Analyses of survival differences by prognostic
factors were performed using Cox regression (Cox, 1972).
Landmark survival analyses were conducted for the subset of
patients completing all therapy, to avoid selection bias
(Anderson et al, 1983). Data as of August 20, 2013 were
included in the analysis.
Results
Patient characteristics
Between November 2005 and March 2010, 86 patients were
registered (Fig 1). Two patients were determined to be ineli-
gible before treatment (one incorrect histology; one CD20-
negative disease). Baseline clinical characteristics are detailed
in Table I.
Treatment
Fifty-six patients (67%) completed the entire course of pro-
tocol treatment (RCHOP + radioimmunotherapy) as
planned. Reasons for early termination included: toxicity
(n = 8 due to left ventricular ejection fraction changes and
neuropathy; infection, backache, and neuropathy; drop in
ejection fraction; infection and neuropathy; thrombocytope-
nia; fatigue; pancytopenia and cirrhosis); refusal unrelated to
adverse events (n = 8), progressive disease (n = 4); death
(n = 3), institutional error (n = 3) and physician decision
(n = 2). Patients who did not receive the full course of
RCHOP/131I tositumomab were more likely to have high-
intermediate/high IPI risk disease compared to those who
Fig 1. CONSORT diagram illustrating patient
flow and study schema on Southwest Oncology
Group protocol S0433. AE, adverse event;
CHOP, cyclophosphamide, doxorubicin, vin-
cristine, prednisone chemotherapy; R-CHOP,
CHOP with rituximab; IT, intrathecal.
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did receive the entire course of planned therapy (64% vs.
34%; P = 0008).
Safety
Five patients experienced Grade 5 toxicities: cardiac ischaemia
(n = 2), febrile neutropenia (n = 1), renal failure (n = 1) and
secondary malignancy (acute myeloid leukaemia, n = 1).
Forty-six additional patients (55%) had at worst Grade 4 tox-
icity, mostly haematological, as detailed in Table II. Common
non-haematological adverse events, occurring in at least 10%
of treated patients, are detailed in Table II.
Efficacy
Of the 84 patients evaluable, 72 (86%, 95% CI: 76–92%)
achieved an objective response to therapy, including partial
response (n = 21) or a confirmed (n = 41) or unconfirmed
(n = 10) complete response based upon prespecified criteria
(Cheson et al, 1999). One additional patient maintained
stable disease. Among the 56 patients that received all
treatment, including 131I tositumomab, 55 (98%, 95% CI:
90–100%) achieved a partial or complete response to
therapy.
The median follow-up of the patients still alive is
39 years. Figure 2 includes the PFS and OS experience of
this cohort. Eight patients (10%) were <60 years with low
IPI. Therefore the weighted target PFS was 73%. The
observed 2-year PFS estimate was 69% (95% CI: 59–79%;
Fig 2). The 2-year OS estimate was 77% (95% CI: 68–86%).
Among the 56 patients that received all CHOP-R/131I tositu-
momab, the 2-year PFS, beginning from 6 months after
registration (i.e. after completion of tositumomab treatment
using landmark analysis), was 75% (95% CI: 64–86%;
Fig 3).
Correlative laboratory studies
Circulating rituximab levels at day 169. Serum rituximab
levels following the eighth cycle of CHOP (drawn at day
169) were studied in 15 patients. Concentration values ran-
ged from 19 100 to 110 000 ng/ml, with a median concen-
tration = 53 500 ng/ml. The proportion of patients with
rituximab levels above the group median that experienced
Grade 3–4 toxicities was 100% as compared to 86% Grade
3–5 toxicities among the patients with circulating ritux-
imab levels below the group median at Day 169
(P = 047).
MYC and BCL2 immunohistochemistry. Baseline tissue was
available for MYC and BCL2 immunohiistochemical analysis
on 75 eligible patients; 79% were BCL2 protein positive, 19%
were MYC protein positive. Of those with both MYC and
BCL2 values (n = 65), 13 (20%) were MYC/BCL2 double
protein positive. Estimated 2-year PFS in double protein
positive patients was 58% (95% CI: 27%, 80%); the 2-year
PFS estimate in non-double positive patients was 73% (95%
Table II. Adverse events on Southwest Oncology Group protocol
S0433. Any Grade 4 or Grade 5 and common (in 10% of patients or
more) Grade 3 events.
Adverse events
(Grade ≥3)
n, % of Patients (total n = 84)
Grade 3
(%)
Grade 4
(%)
Grade 5*
(%)
Cardiovascular 6 (7) 1 (1) 2 (2)
Flu-like symptoms 11 (13) 1 (1) –
Dehydration – 1 (1) –
Other gastrointestinal
event
– 1 (1) –
Haematological
Haemoglobin 12 (14) – –
Leucocytes 23 (27) 24 (29) –
Lymphopenia 24 (29) 15 (18) –
Neutrophils 11 (13) 44 (52) –
Platelets 12 (14) 17 (20) –
GI Haemorrhage: rectum – 1 (1) –
Infection 20 (24) 1 (1) 1 (1)
Pneumonitis – 1 (1) –
Hyperglycaemia – 1 (1) –
Hyperuricaemia – 1 (1) –
Hypokalaemia – 1 (1) –
Neurophathy 9 (11) – –
Renal failure – – 1 (1)
Secondary malignancy 1 (1) – 1 (1)
GI, gastrointestinal.
*Two cardiac ischaemia, 1 febrile neutropenia, 1 renal failure, 1 acute
myeloid leukaemia.
Table I. Characteristics of study participants treated on Southwest
Oncology Group protocol S0433.
Characteristic N = 84 eligible
Age, median (range)
Years 64 (29–85)
Gender, n (%)
Female 45 (54)
Race, n (%)
White 78 (93)
Ethnicity, n (%)
Hispanic 3 (4)
IPI Risk level, n (%)
Low 20 (24)
Low-Intermediate 27 (32)
High-Intermediate 27 (32)
High 10 (12)
Immunohistochemistry, n (%)*
BCL2+ 57 (86)
MYC+ 15 (23)
BCL2 + MYC+ 13 (20)
IPI, international prognostic index.
*Successfully completed on N = 66 subjects.
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CI: 59%, 83%). Despite a trend, neither PFS nor OS were
significantly associated with double protein positive status
(P = 034, and P = 099, respectively).
GCB versus non-GCB status. Of the 22 patients evaluated
for GCB status, 9 (41%) were GCB and 13 (59%) patients
were non-GCB: 6 (67%) GCB and 10 (77%) non-GCB
patients completed full protocol treatment. The estimated
2-year PFS in GCB patients and non-GCB patients was 67%
(95% CI: 28%, 88%); and 85% (95% CI: 51%, 96%),
respectively. Neither PFS nor OS were significantly associated
with GCB versus non-GCB status (P = 097, and P = 056,
respectively).
Discussion
In our clinical trial, a consolidation strategy utilizing 131I to-
situmomab after eight cycles of CHOP chemotherapy (6
with rituximab) for DLBCL did not meet our predefined
threshold (2 year PFS = 73%) for future evaluation. Unlike
our previous experiences in follicular lymphoma (Press et al,
2003, 2013), in this population of DLBCL, early progres-
sions, deaths and declining performance status during
R-CHOP chemotherapy prevented over one quarter of
patients from receiving planned consolidation with radioim-
munotherapy. For those selected patients who were able to
received radioimmunotherapy, the outcome appeared quite
favourable, however this group had lower IPI scores,
and more favourable clinical characteristics compared to
the group of patients who did not receive radioimmuno-
therapy.
Our results stand in contrast to the limited number of
other trials that used radioimmunotherapy as consolidation
after initial chemo-immunotherapy for DLBCL. Zinzani ini-
tially demonstrated feasibility of this concept in a pilot trial
of 20 patients treated with six cycles of CHOP (no ritux-
imab), followed by ibritumomab tiuxetan consolidation,
demonstrating safety and efficacy (Zinzani et al, 2008). The
same group then conducted a larger phase 2 trial in 55 high-
risk elderly patients of an abbreviated (four cycles) course of
R-CHOP followed by ibritumomab tiuxetan consolidation
(Zinzani et al, 2010). Only seven patients (13%) did not
receive planned radioimmunotherapy after abbreviated R-
CHOP, all due to disease progression. The authors reported
an estimated PFS of 85% at 2 years for the entire study pop-
ulation. Hamlin et al (2010), presented preliminary results of
a single institution phase 2 study in elderly patients with
DLBCL, utilizing six cycles of R-CHOP followed by ibritu-
momab tiuxetan consolidation (Hamlin et al, 2010). Of 63
patients enrolled, 19 (30%) did not receive planned radioim-
munotherapy. Similar to our trial, the group of patients who
were able to receive radioimmunotherapy had superior out-
come. Finally, the Southwest Oncology Group (SWOG) has
presented preliminary results of an approach for early stage
DLBCL utilizing three cycles of CHOP (no rituximab),
involved field radiation therapy, and ibritumomab tiuxetan
consolidation, demonstrating higher response rates and
longer PFS than historical controls without radioimmuno-
therapy (Miller et al, 2008).
All of these other trials have utilized ibritumomab tiuxe-
tan instead of 131I tositumomab as the radioimmunotherapy
consolidation strategy. Although there are clear differences
between these agents, the clinical outcomes across various
histologies of lymphomas have been remarkably similar
when using either agent (Schaefer-Cutillo & Friedberg,
(A)
(B)
Fig 2. (A) Progression-free and (B) overall survival of 84 patients
with advanced stage or bulky stage 2 confirmed diffuse large B cell
lymphoma treated with six cycles of cyclophosphamide, doxorubicin,
vincristine, prednisone chemotherapy (CHOP) with rituximab
(R-CHOP), with two additional cycles of CHOP alone, followed by
131I tositumomab.
Fig 3. Progression-free survival among patients who received 131I
tositumomab (progression-free survival started 6 months post-
registration).
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2008). Perhaps more importantly, these other studies utilized
a shorter course of chemotherapy induction prior to consoli-
dation. Although the pivotal studies of the R-CHOP regimen
in advanced DLBCL utilized eight cycles of chemotherapy
(Feugier et al, 2005), many experts now prefer six cycles
as standard treatment, based in part upon the German
experience demonstrating equivalence of 6 versus 8 cycles of
R-CHOP given every 14 d (Pfreundschuh et al, 2008). Given
that many patients in our study were not able to receive
consolidation with radioimmunotherapy due to frailty and
toxic effects of chemotherapy, a shorter course of induction
therapy may have provided a more favourable outcome.
Preclinical studies in mice have suggested that rituximab
concentrations can block the binding of a second anti-CD20
monoclonal antibody, and therefore circulating rituximab
might impair the clinical efficacy of anti-CD20 radioimmu-
notherapy (Gopal et al, 2008). For this reason, we omitted
rituximab for the seventh and eighth cycles of R-CHOP in
our study. Despite this, rituximab levels performed in a sub-
set of patients demonstrated wide variability of circulating
rituximab prior to radioimmunotherapy administration.
Targeting alternative antigens on DLBCL overcomes this
theoretical concern, and a preliminary study of 64 patients
with relapsed lymphoma demonstrated safety and efficacy of
anti-CD22 fractionated radioimmunotherapy with ep-
ratuzumab tetraxetan (Morschhauser et al, 2010). Other
alternative means of delivering radioimmunotherapy include
pretargeting using streptavidin-biotin technology, which in
model systems has demonstrated superior biodistribution,
more complete tumour regressions, and longer survival
compared with conventional radioimmunotherapy (Green
et al, 2007). Finally, the Mayo Clinic group has demon-
strated impressive results when combining a Toll-like recep-
tor 9 agonist, which has demonstrated activity in
combination with rituximab (Friedberg et al, 2005, 2009),
with ibritumomab tiuxetan in patients with relapsed
lymphoma (Witzig et al, 2013).
DLBCL is a heterogeneous disease, and gene expression
profiling studies have identified at least three unique cell-of-
origin profiles with differential therapeutic outcomes (Lenz
et al, 2008). In our study, using immunohistochemistry as a
surrogate for cell-of-origin, patients with non-GCB lym-
phoma had equivalent outcome to patients with GCB histol-
ogy. Recent data has suggested that perhaps the major unmet
clinical need in treatment of DLBCL is to overcome the
adverse prognostic impact of “double hit” histology, defined
by dual overexpression of MYC and BCL2 in DLBCL (Fried-
berg, 2012). When measured by immunohistochemistry
(double protein positive), up to 30% of newly diagnosed
DLBCL can be identified, which portends a dismal prognosis
after R-CHOP treatment (Green et al, 2012; Johnson et al,
2012). The majority of patients with double hit features are
elderly, and new treatments are clearly indicated for this
group (Pfreundschuh, 2012). In our study, the observed rates
of PFS in the 20% of patients with double protein positivity
appeared inferior, which was partly due to early progressions
prior to planned radioimmunotherapy.
A recent trial in relapsed or refractory DLBCL comparing
rituximab and BEAM (carmustine, etoposide, cytarabine,
melphalan) chemotherapy conditioning to 131I tositumomab
and BEAM chemotherapy conditioning prior to ASCT
showed no improvement when radioimmunotherapy was
added to the conditioning regimen (Vose et al, 2013).
GlaxoSmithKline (Philadelphia, PA, USA) has announced
that, effective from February 2014, 131I tositumomab will no
longer be commercially available in the United States. Ibritu-
momab tiuxetan remains commercially available, and indeed
a phase 3 trial is planned to definitively evaluate the role of
radioimmunotherapy consolidation in DLBCL. Based upon
our results, favourable prognosis patients without double hit
histology may benefit the most from this modality. For
patients with high clinical risk features, or double hit fea-
tures by immunohistochemistry, alternative approaches
including the early incorporation of novel agents is prefera-
ble to a consolidation or maintenance approach, due to the
high rate of early disease progression. Currently, SWOG is
evaluating standard R-CHOP chemotherapy with vorinostat
(Crump et al, 2008) in advanced stages of DLBCL, and other
groups are exploring lenalidomide (Chiappella et al, 2013)
and ibrutinib (Younes et al, 2013) in combination with R-
CHOP. Moving forward, as our biological understanding of
DLBCL improves, rational incorporation of novel
approaches, including radioimmunotherapy, should be based
upon biological disease signatures rather than empiricism
(Friedberg, 2011).
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